Amplyx Pharmaceuticals (Monoclonal Antibody MAU868) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Amplyx Pharmaceuticals (Monoclonal Antibody MAU868) General Information

Description

A monoclonal antibody to treat virus infections of kidney transplant patients in San Diego, California.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 12730 High Bluff Drive
  • Suite 160
  • San Diego, CA 92130
  • United States
Primary Industry
Drug Discovery
Corporate Office
  • 12730 High Bluff Drive
  • Suite 160
  • San Diego, CA 92130
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amplyx Pharmaceuticals (Monoclonal Antibody MAU868) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Amplyx Pharmaceuticals (Monoclonal Antibody MAU868)‘s full profile, request access.

Request a free trial

Amplyx Pharmaceuticals (Monoclonal Antibody MAU868) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Amplyx Pharmaceuticals (Monoclonal Antibody MAU868)‘s full profile, request access.

Request a free trial

Amplyx Pharmaceuticals (Monoclonal Antibody MAU868) FAQs

  • Where is Amplyx Pharmaceuticals (Monoclonal Antibody MAU868) headquartered?

    Amplyx Pharmaceuticals (Monoclonal Antibody MAU868) is headquartered in San Diego, CA.

  • What industry is Amplyx Pharmaceuticals (Monoclonal Antibody MAU868) in?

    Amplyx Pharmaceuticals (Monoclonal Antibody MAU868)’s primary industry is Drug Discovery.

  • Is Amplyx Pharmaceuticals (Monoclonal Antibody MAU868) a private or public company?

    Amplyx Pharmaceuticals (Monoclonal Antibody MAU868) is a Private company.

  • What is the current valuation of Amplyx Pharmaceuticals (Monoclonal Antibody MAU868)?

    The current valuation of Amplyx Pharmaceuticals (Monoclonal Antibody MAU868) is .

  • What is Amplyx Pharmaceuticals (Monoclonal Antibody MAU868)’s current revenue?

    The current revenue for Amplyx Pharmaceuticals (Monoclonal Antibody MAU868) is .

  • Who are Amplyx Pharmaceuticals (Monoclonal Antibody MAU868)’s investors?

    Amplyx Pharmaceuticals has invested in Amplyx Pharmaceuticals (Monoclonal Antibody MAU868).

  • When was Amplyx Pharmaceuticals (Monoclonal Antibody MAU868) acquired?

    Amplyx Pharmaceuticals (Monoclonal Antibody MAU868) was acquired on 17-Dec-2021.

  • Who acquired Amplyx Pharmaceuticals (Monoclonal Antibody MAU868)?

    Amplyx Pharmaceuticals (Monoclonal Antibody MAU868) was acquired by Vera Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process